| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10963801 | Vaccine | 2015 | 7 Pages |
Abstract
Estimates of relative efficacy consistently favored IIV-HD over IIV-SD. There was no significant evidence that baseline age, comorbidity, or frailty modified the efficacy of IIV-HD relative to IIV-SD. IIV-HD significantly improved HAI responses for all strains and in all subgroups. IIV-HD is likely to provide benefits beyond IIV-SD for adults â¥65 years, irrespective of age and presence of comorbid or frailty conditions.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Carlos A. DiazGranados, Andrew J. Dunning, Corwin A. Robertson, H. Keipp Talbot, Victoria Landolfi, David P. Greenberg,